Vivani Medical (VANI) and Okava Pharmaceuticals said Tuesday they have expanded their partnership in the development of OKV-119 as a treatment for weight management, diabetes and other cardiometabolic diseases to include dogs.
The companies began the collaboration in 2019 to develop OKV-119 for cats.
Financial terms of the collaboration were not disclosed.